All News

RheumNow Podcast square

PsA All the Way – Unmet Needs

Jack Cush, MD

Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss key advances and modern disease management. We're featuring guest bloggers, hosting Tuesday Night Rheumatology, posting slides and videos, and much more dedicated to PsA.

Read Article
alopecia,areata,bald,hairloss

Baricitinib Efficacy in Alopecia Areata

Jack Cush, MD

The NEJM has published the results of the BRAVE-AA1 and BRAVE-AA2 trials, demonstrating that baricitinib is effective at regrowing hair in alopecia areata (AA) patients, thus paving the way for future regulatory approval for this difficult to treat disorder. 

Read Article
CV,risk,MI,heart,cardiac

Stable Low Risk of Acute Coronary Syndrome in RA

Jack Cush, MD

A Nordic multinational collaborative study examined the risk of acute coronary syndrome (ACS) in rheumatoid arthritis and found a less than 2 fold increased risk of ACS patients initiating biologic disease-modifying antirheumatic drugs (bDMARDs) with little risk variation with short-ter

Read Article
RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Jack Cush, MD

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
RA, hands, MCP, deformity

Low Dose IL-2 Efficacy in Rheumatoid Arthritis

Jack Cush, MD

A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA).

Read Article
GCA temporal artery

Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis

Jack Cush, MD

A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against granulocyte-macrophage colony-stimulating factor [GM-CSF]) is capable of inducing clinical remission.

Read Article
CorEvitas Registry study of Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted in modest, nonsignificant improvement axial outcomes,(irrespective HLA-B27 status), including ASDAS40, BASDAI50, & spinal pain. 31% of pts were B27+ https://t.co/9m9H7PwIIF #PsAlways https://t.co/dYk5GfIdez

Links:

Dr. John Cush RheumNow ( View Tweet)
Network metaanalysis studied 46 RCTs biologics in #PsA. Some TNFi's numerically (not signif) better vsn interleukin inhib for ACR resps, but worse on PASI resps (IL-23, IL-17i had better PASI responses); No diff in enthesitis & dactylitis resps https://t.co/AvnoLRVi6C #PsAlways https://t.co/BSl9hVbIx6

Links:

Dr. John Cush RheumNow ( View Tweet)
#PsA Biologic initiation was associated with a SMALL drop in NSAIDs (51.1 to 42.5%); glucocorticoids (57.4 to 46.9%) and opioids (38.1 to 33.8%) (Initial vs 12 mos later). Pain Rx use study in 5681 PsA, 2180 AS, & 34,047 RA pts #PsAlways https://t.co/wyrT9CVNq8 https://t.co/8vl7e2a63n

Links:

Dr. John Cush RheumNow ( View Tweet)
Differences in Biologic Persistence in PsO and PsA Administrative claims analysis of biologic use in PsO and PsA in French health insurance databases shows that despite widespread biologic use, overall drug persistence was low for PsO and PsA biologics. https://t.co/PtrXu9xyFa https://t.co/RWciF4DqXj

Links:

Dr. John Cush RheumNow ( View Tweet)
New download available. DMARD and Biologic Safety Prescribing https://t.co/zXE7HwgAYU https://t.co/pMQGPU6KCM

Links:

Dr. John Cush RheumNow ( View Tweet)
Lit review of MDA5 antibody-positive clinically amyopathic dermatomyositis w/ ILD - shows limited data from 15 studies, 388 pts, 1 RCT: ? best survival with high-dose steroids + immunosuppressive (CTX or CyA/tacrolimus). Refractory dz Rx w/PLEX, Tofa, RTX https://t.co/LIl23O6x2Y https://t.co/qvISwpr7Mw

Links:

Dr. John Cush RheumNow ( View Tweet)
Network meta-analysis reviewing PsO biologic treatments and QoL reviewed by Dr. K. Gordon at #RNL2022 @RheumNow https://t.co/BV8s1LJ7VX
Dr. Rachel Tate uptoTate ( View Tweet)
Do you use Otezla with biologics in PsA? #RNL2022 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Completed Early RA prevention trials using agents like steroids, RTX, atorvastatin, abatacept No sig difference in steroids, atorvastatin RTX delayed onset but no overall diff Abatacept decreased RA progression at 1.5 years @RheumNow #RNL2022 https://t.co/v7WxI2P7r5
Robert B Chao, MD doctorRBC ( View Tweet)
@Janetbirdope shares her study on real world retention of JAKi vs biologics in #RA #RNL2022 @rheumnow https://t.co/hNxQ8t4LHH
TheDaoIndex KDAO2011 ( View Tweet)
Retention of JAKinibs longer than bDAMRDs in RA Interesting but wonder how this will be affected given new FDA warnings. @RheumNow #RNL2022 https://t.co/Gj2wBFbaAj
Robert B Chao, MD doctorRBC ( View Tweet)
TNFi and pregnancy No association w/ congenital anomalies/infant infection Discontinuation of TNFi before wk 24, increases risk of disease flare Biologic lvls low in breast milk Does not affect vaccine response Live rotavirus vaccine did not cause infection @RheumNow #RNL2022 https://t.co/ZNdjf5qNDb
Robert B Chao, MD doctorRBC ( View Tweet)
ACR recommendations fro TNF biologics during pregnancy! Why stop at third trimester?! i agree do not rock the boat!! @UmaMahadevanIBD @RheumNow #Rnl2022 https://t.co/NEMEV3ThkF
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Pregnancy exposure to biologics didn't increase risk of infection to THE FETUS !! @UmaMahadevanIBD @RheumNow #Rnl2022 https://t.co/rdEaake6ey
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×